Roquefort Therapeutics (LON:ROQ) Shares Down 4% – Should You Sell?

Roquefort Therapeutics plc (LON:ROQ)’s stock price fell 4% during trading on Tuesday . The stock traded as low as GBX 1.54 ($0.02) and last traded at GBX 1.58 ($0.02). 1,571,627 shares were traded during mid-day trading, a decline of 38% from the average session volume of 2,554,864 shares. The stock had previously closed at GBX 1.64 ($0.02).

Roquefort Therapeutics Trading Down 6.3%

The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The company’s 50 day simple moving average is GBX 1.74 and its 200 day simple moving average is GBX 3. The firm has a market cap of £1.91 million, a price-to-earnings ratio of -1.24 and a beta of 0.05.

Roquefort Therapeutics (LON:ROQ) last announced its earnings results on Wednesday, April 30th. The company reported GBX (0.75) (($0.01)) EPS for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.